Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8993146 | Drug Metabolism and Pharmacokinetics | 2005 | 5 Pages |
Abstract
We investigated whether there was a stereoselective effect of amiodarone on the pharmacokinetics of carvedilol. Among a series of 106 inpatients with heart failure, 52 received carvedilol monotherapy (carvedilol group) and 54 received carvedilol plus amiodarone (carvedilol + amiodarone group). The serum carvedilol concentration administered /dose ratio was compared between the two groups based on HPLC measurement of the serum levels of carvedilol, amiodarone, and desethylamiodarone. In 6 patients from the carvedilol group, serum carvedilol levels were compared before and after coadministration of amiodarone. There was no significant between-group difference of the serum concentration to dose (C /D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol + amiodarone group(47.8±56.7 versus 95.3±105ng/mg/kg, P = 0.0048 and 0.460 ± 0.207 versus 0.879 ± 0.377 ng/mg/kg, P < 0.001), respectively. Furthermore, the mean S-carvedilol concentration over 14 days of coadministration with amiodarone was higher than that before coadministration (6.54 ± 1.73 ng/mL versus 3.03±0.670ng/mL, P<0.001). These results suggest that metabolism of S-carvedilol was markedly inhibited by coadministration of amiodarone.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Kyoko Fukumoto, Takashi Kobayashi, Kazuo Komamura, Shiro Kamakura, Masafumi Kitakaze, Kazuyuki Ueno,